nodes	percent_of_prediction	percent_of_DWPC	metapath
Deferoxamine—XDH—Carboplatin—urinary bladder cancer	0.338	0.412	CbGbCtD
Deferoxamine—XDH—Cisplatin—urinary bladder cancer	0.289	0.352	CbGbCtD
Deferoxamine—XDH—Doxorubicin—urinary bladder cancer	0.193	0.236	CbGbCtD
Deferoxamine—XDH—prostate gland—urinary bladder cancer	0.00204	0.367	CbGeAlD
Deferoxamine—XDH—renal system—urinary bladder cancer	0.00139	0.25	CbGeAlD
Deferoxamine—XDH—female reproductive system—urinary bladder cancer	0.00111	0.201	CbGeAlD
Deferoxamine—XDH—vagina—urinary bladder cancer	0.00101	0.181	CbGeAlD
Deferoxamine—Leukopenia—Cisplatin—urinary bladder cancer	0.000287	0.00164	CcSEcCtD
Deferoxamine—Pain—Thiotepa—urinary bladder cancer	0.000285	0.00164	CcSEcCtD
Deferoxamine—Anaphylactoid reaction—Epirubicin—urinary bladder cancer	0.000282	0.00162	CcSEcCtD
Deferoxamine—Muscle spasms—Etoposide—urinary bladder cancer	0.000282	0.00162	CcSEcCtD
Deferoxamine—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.000281	0.00161	CcSEcCtD
Deferoxamine—Oedema—Gemcitabine—urinary bladder cancer	0.000281	0.00161	CcSEcCtD
Deferoxamine—Infection—Gemcitabine—urinary bladder cancer	0.000279	0.0016	CcSEcCtD
Deferoxamine—Convulsion—Cisplatin—urinary bladder cancer	0.000278	0.00159	CcSEcCtD
Deferoxamine—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.000276	0.00158	CcSEcCtD
Deferoxamine—Oedema—Fluorouracil—urinary bladder cancer	0.000276	0.00158	CcSEcCtD
Deferoxamine—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.000275	0.00158	CcSEcCtD
Deferoxamine—Thrombocytopenia—Gemcitabine—urinary bladder cancer	0.000275	0.00157	CcSEcCtD
Deferoxamine—Infection—Fluorouracil—urinary bladder cancer	0.000274	0.00157	CcSEcCtD
Deferoxamine—Renal failure acute—Doxorubicin—urinary bladder cancer	0.000274	0.00157	CcSEcCtD
Deferoxamine—Myalgia—Cisplatin—urinary bladder cancer	0.000273	0.00156	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.000273	0.00156	CcSEcCtD
Deferoxamine—Skin disorder—Gemcitabine—urinary bladder cancer	0.000273	0.00156	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.000271	0.00155	CcSEcCtD
Deferoxamine—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.000271	0.00155	CcSEcCtD
Deferoxamine—Thrombocytopenia—Fluorouracil—urinary bladder cancer	0.00027	0.00155	CcSEcCtD
Deferoxamine—Tachycardia—Fluorouracil—urinary bladder cancer	0.000269	0.00154	CcSEcCtD
Deferoxamine—Renal impairment—Doxorubicin—urinary bladder cancer	0.000266	0.00152	CcSEcCtD
Deferoxamine—Urticaria—Thiotepa—urinary bladder cancer	0.000265	0.00152	CcSEcCtD
Deferoxamine—Abdominal pain—Thiotepa—urinary bladder cancer	0.000264	0.00151	CcSEcCtD
Deferoxamine—Body temperature increased—Thiotepa—urinary bladder cancer	0.000264	0.00151	CcSEcCtD
Deferoxamine—Leukopenia—Etoposide—urinary bladder cancer	0.000263	0.00151	CcSEcCtD
Deferoxamine—Hypotension—Gemcitabine—urinary bladder cancer	0.000262	0.0015	CcSEcCtD
Deferoxamine—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.000262	0.0015	CcSEcCtD
Deferoxamine—Oedema—Cisplatin—urinary bladder cancer	0.000262	0.0015	CcSEcCtD
Deferoxamine—Anaphylactoid reaction—Doxorubicin—urinary bladder cancer	0.000261	0.0015	CcSEcCtD
Deferoxamine—Infection—Cisplatin—urinary bladder cancer	0.00026	0.00149	CcSEcCtD
Deferoxamine—Hypotension—Fluorouracil—urinary bladder cancer	0.000258	0.00148	CcSEcCtD
Deferoxamine—Nervous system disorder—Cisplatin—urinary bladder cancer	0.000256	0.00147	CcSEcCtD
Deferoxamine—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.000256	0.00147	CcSEcCtD
Deferoxamine—Blood creatinine increased—Epirubicin—urinary bladder cancer	0.000256	0.00147	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.000256	0.00147	CcSEcCtD
Deferoxamine—Tachycardia—Cisplatin—urinary bladder cancer	0.000255	0.00146	CcSEcCtD
Deferoxamine—Convulsion—Etoposide—urinary bladder cancer	0.000254	0.00146	CcSEcCtD
Deferoxamine—Skin disorder—Cisplatin—urinary bladder cancer	0.000254	0.00146	CcSEcCtD
Deferoxamine—Asthma—Methotrexate—urinary bladder cancer	0.000252	0.00145	CcSEcCtD
Deferoxamine—Paraesthesia—Gemcitabine—urinary bladder cancer	0.000252	0.00144	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.000251	0.00144	CcSEcCtD
Deferoxamine—Dyspnoea—Gemcitabine—urinary bladder cancer	0.00025	0.00143	CcSEcCtD
Deferoxamine—Eosinophilia—Methotrexate—urinary bladder cancer	0.00025	0.00143	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.000248	0.00142	CcSEcCtD
Deferoxamine—Paraesthesia—Fluorouracil—urinary bladder cancer	0.000248	0.00142	CcSEcCtD
Deferoxamine—Dyspnoea—Fluorouracil—urinary bladder cancer	0.000246	0.00141	CcSEcCtD
Deferoxamine—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000246	0.00141	CcSEcCtD
Deferoxamine—Hypotension—Cisplatin—urinary bladder cancer	0.000244	0.0014	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000242	0.00139	CcSEcCtD
Deferoxamine—Abdominal discomfort—Methotrexate—urinary bladder cancer	0.000242	0.00139	CcSEcCtD
Deferoxamine—Pain—Gemcitabine—urinary bladder cancer	0.00024	0.00138	CcSEcCtD
Deferoxamine—Anaphylactic shock—Etoposide—urinary bladder cancer	0.00024	0.00137	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000238	0.00137	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000238	0.00137	CcSEcCtD
Deferoxamine—Infection—Etoposide—urinary bladder cancer	0.000238	0.00136	CcSEcCtD
Deferoxamine—Blood creatinine increased—Doxorubicin—urinary bladder cancer	0.000237	0.00136	CcSEcCtD
Deferoxamine—Asthma—Epirubicin—urinary bladder cancer	0.000236	0.00135	CcSEcCtD
Deferoxamine—Dysuria—Methotrexate—urinary bladder cancer	0.000236	0.00135	CcSEcCtD
Deferoxamine—Pruritus—Thiotepa—urinary bladder cancer	0.000236	0.00135	CcSEcCtD
Deferoxamine—Pain—Fluorouracil—urinary bladder cancer	0.000236	0.00135	CcSEcCtD
Deferoxamine—Paraesthesia—Cisplatin—urinary bladder cancer	0.000235	0.00135	CcSEcCtD
Deferoxamine—Thrombocytopenia—Etoposide—urinary bladder cancer	0.000235	0.00134	CcSEcCtD
Deferoxamine—Tachycardia—Etoposide—urinary bladder cancer	0.000234	0.00134	CcSEcCtD
Deferoxamine—Eosinophilia—Epirubicin—urinary bladder cancer	0.000234	0.00134	CcSEcCtD
Deferoxamine—Dyspnoea—Cisplatin—urinary bladder cancer	0.000233	0.00134	CcSEcCtD
Deferoxamine—Skin disorder—Etoposide—urinary bladder cancer	0.000233	0.00133	CcSEcCtD
Deferoxamine—Diarrhoea—Thiotepa—urinary bladder cancer	0.000228	0.00131	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000226	0.00129	CcSEcCtD
Deferoxamine—Infestation NOS—Methotrexate—urinary bladder cancer	0.000225	0.00129	CcSEcCtD
Deferoxamine—Infestation—Methotrexate—urinary bladder cancer	0.000225	0.00129	CcSEcCtD
Deferoxamine—Hypotension—Etoposide—urinary bladder cancer	0.000224	0.00128	CcSEcCtD
Deferoxamine—Pain—Cisplatin—urinary bladder cancer	0.000224	0.00128	CcSEcCtD
Deferoxamine—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000222	0.00127	CcSEcCtD
Deferoxamine—Renal failure—Methotrexate—urinary bladder cancer	0.000221	0.00127	CcSEcCtD
Deferoxamine—Dysuria—Epirubicin—urinary bladder cancer	0.000221	0.00127	CcSEcCtD
Deferoxamine—Dizziness—Thiotepa—urinary bladder cancer	0.000221	0.00126	CcSEcCtD
Deferoxamine—Urticaria—Fluorouracil—urinary bladder cancer	0.000219	0.00126	CcSEcCtD
Deferoxamine—Asthma—Doxorubicin—urinary bladder cancer	0.000219	0.00125	CcSEcCtD
Deferoxamine—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000218	0.00125	CcSEcCtD
Deferoxamine—Eosinophilia—Doxorubicin—urinary bladder cancer	0.000216	0.00124	CcSEcCtD
Deferoxamine—Paraesthesia—Etoposide—urinary bladder cancer	0.000215	0.00123	CcSEcCtD
Deferoxamine—Dyspnoea—Etoposide—urinary bladder cancer	0.000214	0.00122	CcSEcCtD
Deferoxamine—Vomiting—Thiotepa—urinary bladder cancer	0.000212	0.00122	CcSEcCtD
Deferoxamine—Infestation NOS—Epirubicin—urinary bladder cancer	0.000211	0.00121	CcSEcCtD
Deferoxamine—Infestation—Epirubicin—urinary bladder cancer	0.000211	0.00121	CcSEcCtD
Deferoxamine—Headache—Thiotepa—urinary bladder cancer	0.000209	0.0012	CcSEcCtD
Deferoxamine—Renal failure—Epirubicin—urinary bladder cancer	0.000207	0.00119	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000207	0.00119	CcSEcCtD
Deferoxamine—Body temperature increased—Cisplatin—urinary bladder cancer	0.000207	0.00119	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Epirubicin—urinary bladder cancer	0.000206	0.00118	CcSEcCtD
Deferoxamine—Pain—Etoposide—urinary bladder cancer	0.000205	0.00117	CcSEcCtD
Deferoxamine—Dysuria—Doxorubicin—urinary bladder cancer	0.000204	0.00117	CcSEcCtD
Deferoxamine—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000203	0.00117	CcSEcCtD
Deferoxamine—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.0002	0.00114	CcSEcCtD
Deferoxamine—Pruritus—Gemcitabine—urinary bladder cancer	0.000199	0.00114	CcSEcCtD
Deferoxamine—Nausea—Thiotepa—urinary bladder cancer	0.000198	0.00114	CcSEcCtD
Deferoxamine—Urethral disorder—Methotrexate—urinary bladder cancer	0.000198	0.00114	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000196	0.00112	CcSEcCtD
Deferoxamine—Pruritus—Fluorouracil—urinary bladder cancer	0.000195	0.00112	CcSEcCtD
Deferoxamine—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000195	0.00112	CcSEcCtD
Deferoxamine—Infestation—Doxorubicin—urinary bladder cancer	0.000195	0.00112	CcSEcCtD
Deferoxamine—Visual impairment—Methotrexate—urinary bladder cancer	0.000195	0.00112	CcSEcCtD
Deferoxamine—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000193	0.0011	CcSEcCtD
Deferoxamine—Bradycardia—Epirubicin—urinary bladder cancer	0.000192	0.0011	CcSEcCtD
Deferoxamine—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000192	0.0011	CcSEcCtD
Deferoxamine—Renal failure—Doxorubicin—urinary bladder cancer	0.000192	0.0011	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000191	0.00109	CcSEcCtD
Deferoxamine—Urticaria—Etoposide—urinary bladder cancer	0.00019	0.00109	CcSEcCtD
Deferoxamine—Abdominal pain—Etoposide—urinary bladder cancer	0.000189	0.00109	CcSEcCtD
Deferoxamine—Body temperature increased—Etoposide—urinary bladder cancer	0.000189	0.00109	CcSEcCtD
Deferoxamine—Eye disorder—Methotrexate—urinary bladder cancer	0.000189	0.00108	CcSEcCtD
Deferoxamine—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000189	0.00108	CcSEcCtD
Deferoxamine—Tinnitus—Methotrexate—urinary bladder cancer	0.000188	0.00108	CcSEcCtD
Deferoxamine—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000187	0.00107	CcSEcCtD
Deferoxamine—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000186	0.00107	CcSEcCtD
Deferoxamine—Urethral disorder—Epirubicin—urinary bladder cancer	0.000185	0.00106	CcSEcCtD
Deferoxamine—Angiopathy—Methotrexate—urinary bladder cancer	0.000183	0.00105	CcSEcCtD
Deferoxamine—Immune system disorder—Methotrexate—urinary bladder cancer	0.000182	0.00105	CcSEcCtD
Deferoxamine—Dizziness—Fluorouracil—urinary bladder cancer	0.000182	0.00105	CcSEcCtD
Deferoxamine—Visual impairment—Epirubicin—urinary bladder cancer	0.000182	0.00104	CcSEcCtD
Deferoxamine—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000182	0.00104	CcSEcCtD
Deferoxamine—Diarrhoea—Cisplatin—urinary bladder cancer	0.000179	0.00103	CcSEcCtD
Deferoxamine—Vomiting—Gemcitabine—urinary bladder cancer	0.000178	0.00102	CcSEcCtD
Deferoxamine—Bradycardia—Doxorubicin—urinary bladder cancer	0.000178	0.00102	CcSEcCtD
Deferoxamine—Eye disorder—Epirubicin—urinary bladder cancer	0.000177	0.00101	CcSEcCtD
Deferoxamine—Hypersensitivity—Etoposide—urinary bladder cancer	0.000177	0.00101	CcSEcCtD
Deferoxamine—Tinnitus—Epirubicin—urinary bladder cancer	0.000176	0.00101	CcSEcCtD
Deferoxamine—Erythema—Methotrexate—urinary bladder cancer	0.000176	0.00101	CcSEcCtD
Deferoxamine—Headache—Gemcitabine—urinary bladder cancer	0.000176	0.00101	CcSEcCtD
Deferoxamine—Vomiting—Fluorouracil—urinary bladder cancer	0.000175	0.00101	CcSEcCtD
Deferoxamine—Headache—Fluorouracil—urinary bladder cancer	0.000173	0.000991	CcSEcCtD
Deferoxamine—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000173	0.00099	CcSEcCtD
Deferoxamine—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000172	0.000985	CcSEcCtD
Deferoxamine—Angiopathy—Epirubicin—urinary bladder cancer	0.000172	0.000983	CcSEcCtD
Deferoxamine—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000171	0.000983	CcSEcCtD
Deferoxamine—Immune system disorder—Epirubicin—urinary bladder cancer	0.000171	0.000979	CcSEcCtD
Deferoxamine—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.00017	0.000977	CcSEcCtD
Deferoxamine—Pruritus—Etoposide—urinary bladder cancer	0.00017	0.000972	CcSEcCtD
Deferoxamine—Arrhythmia—Epirubicin—urinary bladder cancer	0.000169	0.000968	CcSEcCtD
Deferoxamine—Visual impairment—Doxorubicin—urinary bladder cancer	0.000169	0.000966	CcSEcCtD
Deferoxamine—Nausea—Gemcitabine—urinary bladder cancer	0.000167	0.000955	CcSEcCtD
Deferoxamine—Vomiting—Cisplatin—urinary bladder cancer	0.000166	0.000953	CcSEcCtD
Deferoxamine—Vision blurred—Methotrexate—urinary bladder cancer	0.000166	0.00095	CcSEcCtD
Deferoxamine—Erythema—Epirubicin—urinary bladder cancer	0.000165	0.000943	CcSEcCtD
Deferoxamine—Diarrhoea—Etoposide—urinary bladder cancer	0.000164	0.00094	CcSEcCtD
Deferoxamine—Nausea—Fluorouracil—urinary bladder cancer	0.000164	0.000939	CcSEcCtD
Deferoxamine—Eye disorder—Doxorubicin—urinary bladder cancer	0.000163	0.000937	CcSEcCtD
Deferoxamine—Tinnitus—Doxorubicin—urinary bladder cancer	0.000163	0.000935	CcSEcCtD
Deferoxamine—Angiopathy—Doxorubicin—urinary bladder cancer	0.000159	0.00091	CcSEcCtD
Deferoxamine—Dizziness—Etoposide—urinary bladder cancer	0.000158	0.000908	CcSEcCtD
Deferoxamine—Muscle spasms—Epirubicin—urinary bladder cancer	0.000158	0.000907	CcSEcCtD
Deferoxamine—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000158	0.000906	CcSEcCtD
Deferoxamine—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000158	0.000904	CcSEcCtD
Deferoxamine—Leukopenia—Methotrexate—urinary bladder cancer	0.000157	0.000902	CcSEcCtD
Deferoxamine—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000156	0.000896	CcSEcCtD
Deferoxamine—Nausea—Cisplatin—urinary bladder cancer	0.000155	0.000891	CcSEcCtD
Deferoxamine—Vision blurred—Epirubicin—urinary bladder cancer	0.000155	0.000889	CcSEcCtD
Deferoxamine—Convulsion—Methotrexate—urinary bladder cancer	0.000152	0.000873	CcSEcCtD
Deferoxamine—Vomiting—Etoposide—urinary bladder cancer	0.000152	0.000873	CcSEcCtD
Deferoxamine—Erythema—Doxorubicin—urinary bladder cancer	0.000152	0.000873	CcSEcCtD
Deferoxamine—Headache—Etoposide—urinary bladder cancer	0.00015	0.000861	CcSEcCtD
Deferoxamine—Arthralgia—Methotrexate—urinary bladder cancer	0.00015	0.000858	CcSEcCtD
Deferoxamine—Myalgia—Methotrexate—urinary bladder cancer	0.00015	0.000858	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000149	0.000852	CcSEcCtD
Deferoxamine—Leukopenia—Epirubicin—urinary bladder cancer	0.000147	0.000844	CcSEcCtD
Deferoxamine—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000146	0.000839	CcSEcCtD
Deferoxamine—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000144	0.000823	CcSEcCtD
Deferoxamine—Vision blurred—Doxorubicin—urinary bladder cancer	0.000144	0.000823	CcSEcCtD
Deferoxamine—Convulsion—Epirubicin—urinary bladder cancer	0.000143	0.000817	CcSEcCtD
Deferoxamine—Infection—Methotrexate—urinary bladder cancer	0.000143	0.000817	CcSEcCtD
Deferoxamine—Nausea—Etoposide—urinary bladder cancer	0.000142	0.000816	CcSEcCtD
Deferoxamine—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000141	0.000807	CcSEcCtD
Deferoxamine—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000141	0.000806	CcSEcCtD
Deferoxamine—Arthralgia—Epirubicin—urinary bladder cancer	0.00014	0.000803	CcSEcCtD
Deferoxamine—Myalgia—Epirubicin—urinary bladder cancer	0.00014	0.000803	CcSEcCtD
Deferoxamine—Skin disorder—Methotrexate—urinary bladder cancer	0.000139	0.000799	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000139	0.000798	CcSEcCtD
Deferoxamine—Leukopenia—Doxorubicin—urinary bladder cancer	0.000136	0.000781	CcSEcCtD
Deferoxamine—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000134	0.00077	CcSEcCtD
Deferoxamine—Oedema—Epirubicin—urinary bladder cancer	0.000134	0.00077	CcSEcCtD
Deferoxamine—Hypotension—Methotrexate—urinary bladder cancer	0.000134	0.000769	CcSEcCtD
Deferoxamine—Infection—Epirubicin—urinary bladder cancer	0.000133	0.000765	CcSEcCtD
Deferoxamine—Shock—Epirubicin—urinary bladder cancer	0.000132	0.000758	CcSEcCtD
Deferoxamine—Convulsion—Doxorubicin—urinary bladder cancer	0.000132	0.000756	CcSEcCtD
Deferoxamine—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000132	0.000755	CcSEcCtD
Deferoxamine—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000132	0.000754	CcSEcCtD
Deferoxamine—Tachycardia—Epirubicin—urinary bladder cancer	0.000131	0.000751	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000131	0.00075	CcSEcCtD
Deferoxamine—Skin disorder—Epirubicin—urinary bladder cancer	0.00013	0.000748	CcSEcCtD
Deferoxamine—Myalgia—Doxorubicin—urinary bladder cancer	0.00013	0.000743	CcSEcCtD
Deferoxamine—Arthralgia—Doxorubicin—urinary bladder cancer	0.00013	0.000743	CcSEcCtD
Deferoxamine—Paraesthesia—Methotrexate—urinary bladder cancer	0.000129	0.000739	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000129	0.000738	CcSEcCtD
Deferoxamine—Dyspnoea—Methotrexate—urinary bladder cancer	0.000128	0.000734	CcSEcCtD
Deferoxamine—Hypotension—Epirubicin—urinary bladder cancer	0.000126	0.000719	CcSEcCtD
Deferoxamine—Oedema—Doxorubicin—urinary bladder cancer	0.000124	0.000712	CcSEcCtD
Deferoxamine—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000124	0.000712	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000124	0.00071	CcSEcCtD
Deferoxamine—Infection—Doxorubicin—urinary bladder cancer	0.000123	0.000708	CcSEcCtD
Deferoxamine—Pain—Methotrexate—urinary bladder cancer	0.000123	0.000704	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000122	0.000702	CcSEcCtD
Deferoxamine—Shock—Doxorubicin—urinary bladder cancer	0.000122	0.000701	CcSEcCtD
Deferoxamine—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000122	0.000699	CcSEcCtD
Deferoxamine—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000122	0.000698	CcSEcCtD
Deferoxamine—Tachycardia—Doxorubicin—urinary bladder cancer	0.000121	0.000695	CcSEcCtD
Deferoxamine—Skin disorder—Doxorubicin—urinary bladder cancer	0.000121	0.000692	CcSEcCtD
Deferoxamine—Paraesthesia—Epirubicin—urinary bladder cancer	0.000121	0.000691	CcSEcCtD
Deferoxamine—Dyspnoea—Epirubicin—urinary bladder cancer	0.00012	0.000686	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000117	0.000673	CcSEcCtD
Deferoxamine—Hypotension—Doxorubicin—urinary bladder cancer	0.000116	0.000666	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000116	0.000665	CcSEcCtD
Deferoxamine—Pain—Epirubicin—urinary bladder cancer	0.000115	0.000658	CcSEcCtD
Deferoxamine—Urticaria—Methotrexate—urinary bladder cancer	0.000114	0.000654	CcSEcCtD
Deferoxamine—Body temperature increased—Methotrexate—urinary bladder cancer	0.000113	0.00065	CcSEcCtD
Deferoxamine—Abdominal pain—Methotrexate—urinary bladder cancer	0.000113	0.00065	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000113	0.000649	CcSEcCtD
Deferoxamine—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000112	0.00064	CcSEcCtD
Deferoxamine—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000111	0.000635	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.00011	0.00063	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000107	0.000615	CcSEcCtD
Deferoxamine—Urticaria—Epirubicin—urinary bladder cancer	0.000107	0.000612	CcSEcCtD
Deferoxamine—Pain—Doxorubicin—urinary bladder cancer	0.000106	0.000609	CcSEcCtD
Deferoxamine—Abdominal pain—Epirubicin—urinary bladder cancer	0.000106	0.000609	CcSEcCtD
Deferoxamine—Body temperature increased—Epirubicin—urinary bladder cancer	0.000106	0.000609	CcSEcCtD
Deferoxamine—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000106	0.000606	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000102	0.000583	CcSEcCtD
Deferoxamine—Pruritus—Methotrexate—urinary bladder cancer	0.000102	0.000582	CcSEcCtD
Deferoxamine—Hypersensitivity—Epirubicin—urinary bladder cancer	9.9e-05	0.000567	CcSEcCtD
Deferoxamine—Urticaria—Doxorubicin—urinary bladder cancer	9.87e-05	0.000566	CcSEcCtD
Deferoxamine—Abdominal pain—Doxorubicin—urinary bladder cancer	9.82e-05	0.000563	CcSEcCtD
Deferoxamine—Body temperature increased—Doxorubicin—urinary bladder cancer	9.82e-05	0.000563	CcSEcCtD
Deferoxamine—Diarrhoea—Methotrexate—urinary bladder cancer	9.82e-05	0.000563	CcSEcCtD
Deferoxamine—Pruritus—Epirubicin—urinary bladder cancer	9.5e-05	0.000545	CcSEcCtD
Deferoxamine—Dizziness—Methotrexate—urinary bladder cancer	9.49e-05	0.000544	CcSEcCtD
Deferoxamine—Diarrhoea—Epirubicin—urinary bladder cancer	9.19e-05	0.000527	CcSEcCtD
Deferoxamine—Hypersensitivity—Doxorubicin—urinary bladder cancer	9.16e-05	0.000525	CcSEcCtD
Deferoxamine—Vomiting—Methotrexate—urinary bladder cancer	9.13e-05	0.000523	CcSEcCtD
Deferoxamine—Headache—Methotrexate—urinary bladder cancer	8.99e-05	0.000515	CcSEcCtD
Deferoxamine—Dizziness—Epirubicin—urinary bladder cancer	8.88e-05	0.000509	CcSEcCtD
Deferoxamine—Pruritus—Doxorubicin—urinary bladder cancer	8.79e-05	0.000504	CcSEcCtD
Deferoxamine—Vomiting—Epirubicin—urinary bladder cancer	8.54e-05	0.00049	CcSEcCtD
Deferoxamine—Nausea—Methotrexate—urinary bladder cancer	8.53e-05	0.000489	CcSEcCtD
Deferoxamine—Diarrhoea—Doxorubicin—urinary bladder cancer	8.5e-05	0.000487	CcSEcCtD
Deferoxamine—Headache—Epirubicin—urinary bladder cancer	8.41e-05	0.000482	CcSEcCtD
Deferoxamine—Dizziness—Doxorubicin—urinary bladder cancer	8.22e-05	0.000471	CcSEcCtD
Deferoxamine—Nausea—Epirubicin—urinary bladder cancer	7.98e-05	0.000457	CcSEcCtD
Deferoxamine—Vomiting—Doxorubicin—urinary bladder cancer	7.9e-05	0.000453	CcSEcCtD
Deferoxamine—Headache—Doxorubicin—urinary bladder cancer	7.79e-05	0.000446	CcSEcCtD
Deferoxamine—Nausea—Doxorubicin—urinary bladder cancer	7.38e-05	0.000423	CcSEcCtD
